{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:55:35Z","timestamp":1785354935679,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40263-025-01171-x","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T18:20:54Z","timestamp":1741371654000},"page":"485-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington\u2019s Disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Yigal Paul","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leehee","family":"Navon-Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cruz-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Hecker-Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Niethammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0099-8814","authenticated-orcid":false,"given":"Andrew M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Schuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"316","key":"1171_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"5","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;5(316):40\u201350. https:\/\/doi.org\/10.1001\/jama.2016.8655.","journal-title":"JAMA"},{"key":"1171_CR2","doi-asserted-by":"publisher","unstructured":"Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington\u2019s and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-191-4337-1. https:\/\/doi.org\/10.7916\/D8BK1B2D.","DOI":"10.7916\/D8BK1B2D"},{"key":"1171_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"A-C Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, et al. International guidelines for the treatment of Huntington\u2019s disease. Front Neurol. 2019;10:710. https:\/\/doi.org\/10.3389\/fneur.2019.00710.","journal-title":"Front Neurol"},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"M Geva","year":"2016","unstructured":"Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25:3975\u201387. https:\/\/doi.org\/10.1093\/hmg\/ddw238.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-019-1451-2","volume":"1","author":"A Ionescu","year":"2019","unstructured":"Ionescu A, Gradus T, Altman T, Maimon R, Saraf Avraham N, Geva M, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis. 2019;1(10):210. https:\/\/doi.org\/10.1038\/s41419-019-1451-2.","journal-title":"Cell Death Dis"},{"issue":"Pt A","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"D Ryskamp","year":"2017","unstructured":"Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97(Pt A):46\u201359. https:\/\/doi.org\/10.1016\/j.nbd.2016.10.006.","journal-title":"Neurobiol Dis"},{"key":"1171_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","volume":"48","author":"ID Grachev","year":"2021","unstructured":"Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, et al. Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. Eur J Nucl Med Mol Imaging. 2021;48:1103\u201315. https:\/\/doi.org\/10.1007\/s00259-020-05030-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1171_CR8","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1007\/s12035-021-02524-5","volume":"58","author":"NH Wu","year":"2021","unstructured":"Wu NH, Ye Y, Wan BB, Yu YD, Liu C, Chen QJ. Emerging benefits: pathophysiological functions and target drugs of the sigma-1 receptor in neurodegenerative diseases. Mol Neurobiol. 2021;58:5649\u201366. https:\/\/doi.org\/10.1007\/s12035-021-02524-5.","journal-title":"Mol Neurobiol"},{"key":"1171_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105857","author":"S Lenoir","year":"2022","unstructured":"Lenoir S, Lahaye RA, Vitet H, Scaramuzzino C, Virlogeux A, Capellano L, et al. Pridopidine rescues BDNF\/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiol Dis. 2022. https:\/\/doi.org\/10.1016\/j.nbd.2022.105857.","journal-title":"Neurobiol Dis"},{"key":"1171_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","volume":"18","author":"L Naia","year":"2021","unstructured":"Naia L, Ly P, Mota SI, Lopes C, Maranga C, Coelho P, et al. The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models. Neurotherapeutics. 2021;18:1017\u201338. https:\/\/doi.org\/10.1007\/s13311-021-01022-9.","journal-title":"Neurotherapeutics"},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","volume":"124","author":"D Ryskamp","year":"2019","unstructured":"Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer\u2019s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489\u2013504. https:\/\/doi.org\/10.1016\/j.nbd.2018.12.022.","journal-title":"Neurobiol Dis"},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.15366","volume":"158","author":"M Shenkman","year":"2021","unstructured":"Shenkman M, Geva M, Gershoni-Emek N, Hayden MR, Lederkremer GZ. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the sigma-1 receptor. J Neurochem. 2021;158:467\u201381. https:\/\/doi.org\/10.1111\/jnc.15366.","journal-title":"J Neurochem"},{"key":"1171_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/15548627.2022.2063003","volume":"19","author":"SM Wang","year":"2023","unstructured":"Wang SM, Wu HE, Yasui Y, Geva M, Hayden M, Maurice T, et al. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1\/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023;19:126\u201351. https:\/\/doi.org\/10.1080\/15548627.2022.2063003.","journal-title":"Autophagy"},{"key":"1171_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2019","unstructured":"Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18:165\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(18)30391-0.","journal-title":"Lancet Neurol"},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG de Yebenes","year":"2011","unstructured":"de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:1049\u201357. https:\/\/doi.org\/10.1016\/S1474-4422(11)70233-2.","journal-title":"Lancet Neurol"},{"key":"1171_CR16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Huntington Study Group HART Investigators","year":"2013","unstructured":"Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28:1407\u201315. https:\/\/doi.org\/10.1002\/mds.25362.","journal-title":"Mov Disord"},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40120-023-00449-w","volume":"12","author":"B Darpo","year":"2023","unstructured":"Darpo B, Geva M, Ferber G, Goldberg YP, Cruz-Herranz A, Mehra M, et al. Pridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic dose. Neurol Ther. 2023;12:597\u2013617. https:\/\/doi.org\/10.1007\/s40120-023-00449-w.","journal-title":"Neurol Ther."},{"key":"1171_CR18","unstructured":"ICH.org [Internet]. ICH harmonised tripartite guideline E14. Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. https:\/\/www.ich.org\/page\/efficacy-guidelines Accessed 13 Aug 2024."},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2022.11.004","volume":"105","author":"RL Andriessen","year":"2022","unstructured":"Andriessen RL, Oosterloo M, Hollands A, Linden DEJ, de Greef BTA, Leentjens AFG. Psychotropic medication use in Huntington\u2019s disease: a retrospective cohort study. Parkinsonism Relat Disord. 2022;105:69\u201374. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.11.004.","journal-title":"Parkinsonism Relat Disord"},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki J. Evidence-based guideline: pharmacologic treatment of chorea in huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79:597\u2013603. https:\/\/doi.org\/10.1212\/WNL.0b013e318263c443.","journal-title":"Neurology"},{"key":"1171_CR21","doi-asserted-by":"publisher","unstructured":"Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry, 14th edition. Chichester: Wiley Blackwell; 2021. https:\/\/doi.org\/10.1002\/9781119870203","DOI":"10.1002\/9781119870203"},{"key":"1171_CR22","doi-asserted-by":"publisher","unstructured":"Tedroff J, Waters S, Barker RA, Roos R, Squitieri F, EHDN Registry Study Group. Antidopaminergic medication is associated with more rapidly progressive Huntington\u2019s disease. J Huntingtons Dis. 2015;4:131\u201340. https:\/\/doi.org\/10.3233\/JHD-150143.","DOI":"10.3233\/JHD-150143"},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/jnnp-2019-322038","volume":"91","author":"KL Harris","year":"2020","unstructured":"Harris KL, Kuan WL, Mason SL, Barker RA. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington\u2019s disease (Enroll-HD). J Neurol Neurosurg Psychiatry. 2020;91:622\u201330. https:\/\/doi.org\/10.1136\/jnnp-2019-322038.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1171_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678484","volume":"12","author":"N Ghazaleh","year":"2021","unstructured":"Ghazaleh N, Houghton R, Palermo G, Schobel SA, Wijeratne PA, Long JD. Ranking the predictive power of clinical and biological features associated with disease progression in Huntington\u2019s disease. Front Neurol. 2021;12: 678484. https:\/\/doi.org\/10.3389\/fneur.2021.678484.","journal-title":"Front Neurol"},{"key":"1171_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1600-0447.1991.tb05511.x","volume":"83","author":"S Pflanz","year":"1991","unstructured":"Pflanz S, Besson JA, Ebmeier KP, Simpson S. The clinical manifestation of mental disorder in Huntington\u2019s disease: a retrospective case record study of disease progression. Acta Psychiatr Scand. 1991;83:53\u201360. https:\/\/doi.org\/10.1111\/j.1600-0447.1991.tb05511.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1171_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1017\/s109285290002201x","volume":"6","author":"JR Slaughter","year":"2001","unstructured":"Slaughter JR, Martens MP, Slaughter KA. Depression and Huntington\u2019s disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectr. 2001;6:306\u201326. https:\/\/doi.org\/10.1017\/s109285290002201x.","journal-title":"CNS Spectr"},{"key":"1171_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11940-012-0165-x","volume":"14","author":"A Killoran","year":"2012","unstructured":"Killoran A, Biglan KM. Therapeutics in Huntington\u2019s disease. Curr Treat Options Neurol. 2012;14:137\u201349. https:\/\/doi.org\/10.1007\/s11940-012-0165-x.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1171_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft C, Burgunder JM, Dose M, Jung HH, Katzenschlager R, Priller J, et al. Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society). Neurol Res Pract. 2023;5(1):61. https:\/\/doi.org\/10.1186\/s42466-023-00285-1.","journal-title":"Neurol Res Pract."},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jad.2011.10.031","volume":"136","author":"AA Hubers","year":"2012","unstructured":"Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC. Suicidality in Huntington\u2019s disease. J Affect Disord. 2012;136:550\u20137. https:\/\/doi.org\/10.1016\/j.jad.2011.10.031.","journal-title":"J Affect Disord"},{"key":"1171_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jad.2013.06.001","volume":"151","author":"AA Hubers","year":"2013","unstructured":"Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, et al. Suicidal ideation in a European Huntington\u2019s disease population. J Affect Disord. 2013;151:248\u201358. https:\/\/doi.org\/10.1016\/j.jad.2013.06.001.","journal-title":"J Affect Disord"},{"key":"1171_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1176\/appi.ajp.162.4.725","volume":"162","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington\u2019s disease. Am J Psychiatry. 2005;162:725\u201331. https:\/\/doi.org\/10.1176\/appi.ajp.162.4.725.","journal-title":"Am J Psychiatry"},{"issue":"188","key":"1171_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","volume":"15","author":"HH Wetzel","year":"2011","unstructured":"Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;15(188):372\u20136. https:\/\/doi.org\/10.1016\/j.psychres.2011.05.006.","journal-title":"Psychiatry Res"},{"key":"1171_CR33","unstructured":"Tetrabenazine (Xenazine\u00ae) Highlights of prescribing information. Tablets for oral use. Lundbeck. Last revised: November 2019. https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/united-states\/products\/neurology\/xenazine_pi_us_en.pdf. Accessed 01 Oct 2024."},{"key":"1171_CR34","doi-asserted-by":"publisher","unstructured":"Geva M, Reilmann R, Feigin A, Rosser A, Kostyk S, Chen K, et al. Analyses of the phase 3 trial of pridopidine\u2019s outcome on function in Huntington disease (PROOF-HD) demonstrates efficacy in participants without antidopaminergic medications (S30.002). Neurology. 2024;102 (17_supplement_1). https:\/\/doi.org\/10.1212\/WNL.0000000000208206.","DOI":"10.1212\/WNL.0000000000208206"},{"issue":"80","key":"1171_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1212\/WNL.0b013e3182886965","volume":"19","author":"F Squitieri","year":"2013","unstructured":"Squitieri F, Landwehrmeyer B, Reilmann R, Rosser A, de Yebenes JG, Prang A, et al. One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology. 2013;19(80):1086\u201394. https:\/\/doi.org\/10.1212\/WNL.0b013e3182886965.","journal-title":"Neurology"},{"key":"1171_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JHD-170241","volume":"6","author":"A McGarry","year":"2017","unstructured":"McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, et al. Safety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington\u2019s disease. J Huntingtons Dis. 2017;6:189\u201399. https:\/\/doi.org\/10.3233\/JHD-170241.","journal-title":"J Huntingtons Dis."},{"key":"1171_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3233\/JHD-190393","volume":"9","author":"A McGarry","year":"2020","unstructured":"McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, et al. Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9:173\u201384. https:\/\/doi.org\/10.3233\/JHD-190393.","journal-title":"J Huntingtons Dis."},{"key":"1171_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/acn3.51252","volume":"8","author":"L Ishihara","year":"2021","unstructured":"Ishihara L, Oliveri D, Wild EJ. Neuropsychiatric comorbidities in Huntington\u2019s and Parkinson\u2019s Disease: a United States claims database analysis. Ann Clin Transl Neurol. 2021;8:126\u201337. https:\/\/doi.org\/10.1002\/acn3.51252.","journal-title":"Ann Clin Transl Neurol"},{"key":"1171_CR39","doi-asserted-by":"publisher","unstructured":"Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, et al. Medication use in early-HD participants in track-HD: an investigation of its effects on clinical performance. PLoS Curr. 2016;8. https:\/\/doi.org\/10.1371\/currents.hd.8060298fac1801b01ccea6acc00f97cb.","DOI":"10.1371\/currents.hd.8060298fac1801b01ccea6acc00f97cb"},{"key":"1171_CR40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10072-020-04265-0","volume":"41","author":"N Pizzorni","year":"2020","unstructured":"Pizzorni N, Pirola F, Ciammola A, Schindler A. Management of dysphagia in Huntington\u2019s disease: a descriptive review. Neurol Sci. 2020;41:1405\u201317. https:\/\/doi.org\/10.1007\/s10072-020-04265-0.","journal-title":"Neurol Sci"},{"key":"1171_CR41","doi-asserted-by":"publisher","unstructured":"Heemskerk AW, Roos RA. Aspiration pneumonia and death in Huntington\u2019s disease. PLoS Curr. 2012;4:RRN1293. https:\/\/doi.org\/10.1371\/currents.RRN1293.","DOI":"10.1371\/currents.RRN1293"},{"key":"1171_CR42","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/bcp.13317","volume":"83","author":"L Rabinovich-Guilatt","year":"2017","unstructured":"Rabinovich-Guilatt L, Steiner L, Hallak H, Pastino G, Muglia P, Spiegelstein O. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington\u2019s disease. Br J Clin Pharmacol. 2017;83:2214\u201324. https:\/\/doi.org\/10.1111\/bcp.13317.","journal-title":"Br J Clin Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01171-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01171-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01171-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:17:28Z","timestamp":1744219048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01171-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01171-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"11 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no funding to report. Open access funding was provided by Prilenia Therapeutics B.V.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L.N.P., A.C.H., K.C., A.M.T., Y.C., H.S., and M.G. are employees of Prilenia Therapeutics B.V. and may have stock options in the company. M.R.H. is the CEO and scientific co-founder of Prilenia Neurotherapeutics B.V. He is also a Physician Scientist and University Killam Professor at the University of British Columbia. M.R.H. serves on the Board of Directors for Ionis Pharmaceuticals (San Diego), 89Bio (San Francisco), AbCellera (Vancouver), and Oxford Biomedica (Oxford) (2022\u20132024). Y.P.G. has stock options in Prilenia. The remaining authors declare no conflicts of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study are based on an integrated safety analysis of pooled data from 1067 patients across four double-blind, placebo-controlled clinical trials: PROOF-HD (NCT04556656, EudraCT no. 2020-002822-10), PRIDE-HD (NCT02006472, EudraCT no. 2013-001888-23), MermaiHD (NCT00665223, EudraCT no. 2007-004988-22), and HART (NCT00724048). Data requests for these trials can be requested from the corresponding author, subject to ethical and regulatory considerations.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study was conceived by Y.P.G., M.G., M.N., M.R.H., and Y.C., who also contributed to writing and developing the manuscript. L.N.P., A.C.H., K.S., A.M.T., and H.S. contributed to writing and editing, with K.S. also providing intellectual and editorial support. K.C. handled data analysis and management support, while M.N. and M.R.H. provided further guidance.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}